By combining an FDA-approved cancer immunotherapy with an emerging tumor-roasting nanotechnology, Duke University researchers improved the efficacy of both therapies in a proof-of-concept study using mice.
By combining an FDA-approved cancer immunotherapy with an emerging tumor-roasting nanotechnology, Duke University researchers improved the efficacy of both therapies in a proof-of-concept study using mice.